Precision Brain Copper Imaging for Neurological Diagnostics
A Biomedical Device for Precision Imaging of Copper Levels in the CNS
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
This biomedical device uses a dual-modality molecular probe to precisely measure copper levels in the brain, addressing a critical gap in diagnosing and managing neurological disorders like Parkinson’s disease and ALS. Combining fluorescence imaging and PET scans, the probe enables non-invasive, in vivo copper quantification, activated only in the presence of cellular copper for accurate assessment. Applications include early diagnosis, monitoring, and personalized treatment of copper-related diseases and cancers, as well as research into copper’s role in the CNS. Developed by the University of Sydney, the technology is protected by a provisional patent (2022900560). This innovation offers a significant leap forward in copper dysregulation management and related therapeutic interventions.
IP Type or Form Factor: Patent Pending; Device; Material
TRL: 3 - proof of concept with needs validated
Industry or Tech Area: Diagnostics & Screening; Healthcare Provider
